These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 20039891)

  • 1. Failure of rituximab treatment in a case of severe thyroid ophthalmopathy unresponsive to steroids.
    Krassas GE; Stafilidou A; Boboridis KG
    Clin Endocrinol (Oxf); 2010 Jun; 72(6):853-5. PubMed ID: 20039891
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression.
    Salvi M; Vannucchi G; Campi I; Rossi S; Bonara P; Sbrozzi F; Guastella C; Avignone S; Pirola G; Ratiglia R; Beck-Peccoz P
    Eur J Endocrinol; 2006 Apr; 154(4):511-7. PubMed ID: 16556712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Biological treatment options for Graves' ophthalmopathy].
    El Fassi D; Nielsen CH; Hegedüs L
    Ugeskr Laeger; 2008 Jun; 170(24):2128-30. PubMed ID: 18565294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study.
    Salvi M; Vannucchi G; Campi I; Currò N; Dazzi D; Simonetta S; Bonara P; Rossi S; Sina C; Guastella C; Ratiglia R; Beck-Peccoz P
    Eur J Endocrinol; 2007 Jan; 156(1):33-40. PubMed ID: 17218723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence of orbital B and T cell depletion after rituximab therapy in Graves' ophthalmopathy.
    Nielsen JF; El Fassi D; Nielsen CH; Hegedüs L; Lauer SA; Silkiss RZ; Prause JU
    Acta Ophthalmol; 2009 Nov; 87(8):927-9. PubMed ID: 19785644
    [No Abstract]   [Full Text] [Related]  

  • 6. Rituximab for thyroid eye disease.
    Oh SR; Priel A; Levi L; Granet DB; Korn BS; Kikkawa DO
    Ophthalmology; 2011 Apr; 118(4):792; author reply 792-3. PubMed ID: 21459230
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunotherapy for Graves' ophthalmopathy.
    Salvi M
    Curr Opin Endocrinol Diabetes Obes; 2014 Oct; 21(5):409-14. PubMed ID: 25105999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful Treatment for Severe Thyroid-associated Ophthalmopathy with Tocilizumab.
    Canas CA; Bonilla-Abadia F; Vallejo K; Rengifo HM; Gallon MA; Tobon GJ
    Endocr Metab Immune Disord Drug Targets; 2018; 18(6):665-667. PubMed ID: 29962351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study.
    El Fassi D; Nielsen CH; Bonnema SJ; Hasselbalch HC; Hegedüs L
    J Clin Endocrinol Metab; 2007 May; 92(5):1769-72. PubMed ID: 17284622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab is effective for extensive steroid-refractory chronic graft-vs.-host-disease.
    Carella AM; Biasco S; Nati S; Congiu A; Lerma E
    Leuk Lymphoma; 2007 Mar; 48(3):623-4. PubMed ID: 17454609
    [No Abstract]   [Full Text] [Related]  

  • 11. [Rituximab for treatment of graves orbitopathy].
    Huerva V
    Arch Soc Esp Oftalmol; 2011 May; 86(5):162-3. PubMed ID: 21624658
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletion.
    El Fassi D; Nielsen CH; Hasselbalch HC; Hegedüs L
    Thyroid; 2006 Jul; 16(7):709-10. PubMed ID: 16889501
    [No Abstract]   [Full Text] [Related]  

  • 13. Successful treatment of psoriatic arthritis with rituximab.
    Cohen JD
    Ann Rheum Dis; 2008 Nov; 67(11):1647-8. PubMed ID: 18854517
    [No Abstract]   [Full Text] [Related]  

  • 14. Viral conjunctivitis interfering with the clinical activity score and management of thyroid ophthalmopathy.
    Boboridis KG; Konstas AG; Krassas GE; Georgiadis NS
    Orbit; 2006 Mar; 25(1):27-9. PubMed ID: 16527772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab (Rituxan) therapy for severe thyroid-associated ophthalmopathy diminishes IGF-1R(+) T cells.
    McCoy AN; Kim DS; Gillespie EF; Atkins SJ; Smith TJ; Douglas RS
    J Clin Endocrinol Metab; 2014 Jul; 99(7):E1294-9. PubMed ID: 24670080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum BAFF concentrations in patients with Graves' disease and orbitopathy before and after immunosuppressive therapy.
    Vannucchi G; Covelli D; Currò N; Dazzi D; Maffini A; Campi I; Bonara P; Guastella C; Pignataro L; Ratiglia R; Beck-Peccoz P; Salvi M
    J Clin Endocrinol Metab; 2012 May; 97(5):E755-9. PubMed ID: 22399512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New immunomodulators in treatment of Graves'ophtalmopathy].
    Josseaume C; Lorcy Y
    Ann Endocrinol (Paris); 2008 Sep; 69 Suppl 1():S29-32. PubMed ID: 18954856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Thyroid ophthalmopathy: clinical activity determination of thyroid ophthalmopathy as a prognostic factor of immunosuppressive treatment response].
    Belzunce-Manterola A; García-Gómez PJ; Casellas-Bravo M; Heras-Mulero H; Moreno-Montañés J
    Arch Soc Esp Oftalmol; 2005 Dec; 80(12):705-12. PubMed ID: 16372213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: effects on orbital lymphocytic infiltrates.
    Salvi M; Vannucchi G; Campi I; Currò N; Simonetta S; Covelli D; Pignataro L; Guastella C; Rossi S; Bonara P; Dazzi D; Ratiglia R; Beck-Peccoz P
    Clin Immunol; 2009 May; 131(2):360-5. PubMed ID: 19195932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab in the treatment of thyroid eye disease: science fiction?
    Salvi M; Vannucchi G; Campi I; Beck-Peccoz P
    Orbit; 2009; 28(4):251-5. PubMed ID: 19839884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.